Trials / Completed
CompletedNCT01296581
Safety Study of X-82 in Patients With Advanced Solid Tumors
Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Tyrogenex · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | X-82 | Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2014-01-01
- Completion
- 2017-01-01
- First posted
- 2011-02-15
- Last updated
- 2022-02-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01296581. Inclusion in this directory is not an endorsement.